StemRIM (4599.T)
JPY 298.0
(0.0%)
JPY 298.0
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 | - JPY | -100.0% |
| 2023 | 531 Thousand JPY | -85.54% |
| 2022 | 3.67 Million JPY | -45.46% |
| 2021 | 6.73 Million JPY | -30.68% |
| 2020 | 9.71 Million JPY | -23.02% |
| 2019 | 12.61 Million JPY | 0.0% |
| 2018 | - JPY | 0.0% |
| 2017 | - JPY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | - JPY | 0.0% |
| 2024 Q1 | - JPY | -100.0% |
| 2024 Q4 | - JPY | 0.0% |
| 2024 Q3 | - JPY | 0.0% |
| 2023 Q3 | 1.32 Million JPY | -37.31% |
| 2023 Q2 | 2.11 Million JPY | -27.05% |
| 2023 Q4 | 531 Thousand JPY | -59.89% |
| 2023 Q1 | 2.89 Million JPY | -21.16% |
| 2023 FY | 531 Thousand JPY | -85.54% |
| 2022 Q3 | 4.44 Million JPY | -14.72% |
| 2022 Q2 | 5.21 Million JPY | -12.77% |
| 2022 Q1 | 5.97 Million JPY | -11.26% |
| 2022 Q4 | 3.67 Million JPY | -17.39% |
| 2022 FY | 3.67 Million JPY | -45.46% |
| 2021 Q4 | 6.73 Million JPY | -10.05% |
| 2021 FY | 6.73 Million JPY | -30.68% |
| 2021 Q1 | 8.97 Million JPY | -7.6% |
| 2021 Q3 | 7.48 Million JPY | -9.09% |
| 2021 Q2 | 8.23 Million JPY | -8.27% |
| 2020 Q4 | 9.71 Million JPY | -7.02% |
| 2020 Q2 | 11.17 Million JPY | -6.08% |
| 2020 Q1 | 11.89 Million JPY | -5.7% |
| 2020 FY | 9.71 Million JPY | -23.02% |
| 2020 Q3 | 10.44 Million JPY | -6.52% |
| 2019 Q4 | 12.61 Million JPY | -5.36% |
| 2019 Q3 | 13.33 Million JPY | 0.0% |
| 2019 FY | 12.61 Million JPY | 0.0% |
| 2018 FY | - JPY | 0.0% |
| 2017 FY | - JPY | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 2.46 Billion JPY | 100.0% |
| PRISM BioLab Co.,LTD | - JPY | NaN% |
| GNI Group Ltd. | 3.69 Billion JPY | 100.0% |
| Linical Co., Ltd. | 3 Billion JPY | 100.0% |
| Trans Genic Inc. | 2.25 Billion JPY | 100.0% |
| MEDINET Co., Ltd. | 2.3 Million JPY | 100.0% |
| Soiken Holdings Inc. | - JPY | NaN% |
| Cytori Cell Research Institute, Inc. | 2.47 Billion JPY | 100.0% |
| AnGes, Inc. | 362.67 Million JPY | 100.0% |
| OncoTherapy Science, Inc. | 106.84 Million JPY | 100.0% |
| Nxera Pharma Co., Ltd. | 73.97 Billion JPY | 100.0% |
| Immuno-Biological Laboratories Co., Ltd. | 235.98 Million JPY | 100.0% |
| NanoCarrier Co., Ltd. | 1.1 Billion JPY | 100.0% |
| Carna Biosciences, Inc. | 182.97 Million JPY | 100.0% |
| CanBas Co., Ltd. | - JPY | NaN% |
| D. Western Therapeutics Institute, Inc. | 885.12 Million JPY | 100.0% |
| RaQualia Pharma Inc. | 367.71 Million JPY | 100.0% |
| Chiome Bioscience Inc. | 291 Million JPY | 100.0% |
| Kidswell Bio Corporation | 2.57 Billion JPY | 100.0% |
| PeptiDream Inc. | 22.79 Billion JPY | 100.0% |
| Oncolys BioPharma Inc. | 315.17 Million JPY | 100.0% |
| Ribomic Inc. | - JPY | NaN% |
| SanBio Company Limited | 665 Million JPY | 100.0% |
| Healios K.K. | 4.53 Billion JPY | 100.0% |
| BrightPath Biotherapeutics Co., Ltd. | 112.5 Million JPY | 100.0% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 142.85 Million JPY | 100.0% |
| Delta-Fly Pharma, Inc. | - JPY | NaN% |
| CellSource Co., Ltd. | 97.54 Million JPY | 100.0% |
| FunPep Company Limited | - JPY | NaN% |
| Kringle Pharma, Inc. | - JPY | NaN% |
| Stella Pharma Corporation | 933.3 Million JPY | 100.0% |
| TMS Co., Ltd. | - JPY | NaN% |
| Noile-Immune Biotech Inc. | - JPY | NaN% |
| Cuorips Inc. | - JPY | NaN% |
| K Pharma,Inc. | - JPY | NaN% |
| Takara Bio Inc. | 968 Million JPY | 100.0% |
| ReproCELL Incorporated | - JPY | NaN% |
| PhoenixBio Co., Ltd. | 723.93 Million JPY | 100.0% |
| StemCell Institute Inc. | 8.78 Million JPY | 100.0% |
| Japan Tissue Engineering Co., Ltd. | - JPY | NaN% |
| CellSeed Inc. | 151.25 Million JPY | 100.0% |